Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

CLASS II -- HYDROCODONE BITARTRATE AND ACETAMINOPHEN TABLETS 5 mg/500 mg, in bottles of 100, 500 and 1,000, for the relief of pain, under the following labels: Blue Cross, Schein Pharmaceuticals, Aligen Independent Laboratories, Goldline, Qualitest, Mason, Moore, IDE Star, URL, Par-Med, Major Pharmaceuticals and Halsey Drug. Recall number: D-046-4. All lots, sizes and labels. Manufacturer: Halsey Drug Company, Inc., Brooklyn, New York. Recalled by: Manufacturer, by letter Nov. 10, 1993. Firm- initiated recall ongoing. Distribution: Nationwide; approximately 450 batches of 1,000,000 tablets each were distributed in the last 3 years. Reason: Abbreviated New Drug Application discrepancies. CLASS III -- GUAIFENESIN AND CODEINE PHOSPHATE SYRUP COUGH PREPARATIONS Tusscidin AC Expectorant Cough Suppressant, 4-fluid ounces and 8- fluid ounces; Tusscidin AC Expectorant Cough Suppressant, 128-fluid ounces; Guiatuss AC Syrup, cough suppressant expectorant, 4-fluid ounces, 1 pint and 1 gallon, manufactured for Goldline Laboratories; Guaifenesin A.C. Syrup, 1 pint (473 ml), manufactured for United Research Laboratories, Inc. Recall number: D-037-4. All lots and codes manufactured between Sept. 25, 1993 and Oct. 13, 1993. Manufacturer: H. R. Cenci Laboratories, Inc., Fresno, California. Recalled by: Manufacturer, by letter October 1993. Firm-initiated field correction complete. Distribution: California, Hawaii, Florida, New Jersey, Ohio, Oregon, Pennsylvania, Texas; firm estimates that about 10,000 units covering all sizes remain on the market. Reason: Product does not meet USP specifications for pH. CLASS III -- SPS SUSPENSION (SODIUM POLYSTYRENE SULFONATE SUSPENSION USP) 473 ml, 120 ml and 60 ml. Recall number: D-036-4. Lot numbers: 473 ml - lots - 192271, 292241, 492101, 692111, 792311, 1092081, 1292011, 193221, 293151, 393161, 593061, 693171, 893191, 993031, 120 ml - lots 492031, 1092271, 993271; 60 ml - lots 192081, 192151, 292123, 392131, 592081, 792141, 892133, 992171, 1092291, 1292031, 193112, 293191, 393101, 493291, 693031, 793291, 893301. Manufacturer: Carolina Medical Products Company, Farmville, North Carolina. Recalled by: Manufacturer, by letters sent the week of Nov. 8, 1993, followed by telephone. Firm-initiated recall ongoing. Distribution: Nationwide; 1,500 473-ml bottles; 200 120-ml bottles; 21,000 60-ml units were distributed. Reason: Use of non-approved formulation. CLASS III -- TRIFLUOPERAZINE HYDROCHLORIDE CONCENTRATE 10 mg/ml, in 2-fluid ounce containers, indicated for the management of manifestations of psychotic disorders as well as the short term treatment of non-psychotic anxiety, where it is considered second- line therapy. Recall number: D-038-4. Lot number 73416. Manufacturer: Geneva Pharmaceuticals, Inc., Broomfield, Colorado. Recalled by: Manufacturer, by letter Nov. 22,1993. Firm-initiated recall ongoing. Distribution: Nationwide; 10,023 units were distributed. Reason: Product does not meet stability specifications. UPDATE: Percodan Tablets Recall #D-029-4, which appeared in the Nov. 24, 1993 "Enforcement Report" ["The Pink Sheet" Nov. 29, T&G-15] should read: Lot #EEA- 001A.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts